Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
  • Patent number: 8921386
    Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: December 30, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
  • Publication number: 20140378401
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: December 18, 2013
    Publication date: December 25, 2014
    Applicant: GNT, LLC
    Inventor: Gerald Horn
  • Publication number: 20140371323
    Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.
    Type: Application
    Filed: March 30, 2012
    Publication date: December 18, 2014
    Applicant: Novartis AG
    Inventor: Supriya Rane
  • Publication number: 20140363516
    Abstract: The present invention relates to a sustained-release pharmaceutical formulation, in particular a multiple unit pellet tablet (MUT) formulation for oral administration comprising a plurality of sustained-release pellets. The invention further relates to sustained-release pellets wherein the active agent is an opioid. The sustained-release pellets are suitable for the preparation of a multiple unit pellet tablet formulation.
    Type: Application
    Filed: December 18, 2012
    Publication date: December 11, 2014
    Applicant: Hexal Aktiengesellschaft
    Inventors: Patrick Rother, Andreas Krekeler, Theresa Taeubrich, Christian Wawra, Ingeborg Mohry
  • Patent number: 8906419
    Abstract: The present invention is directed to a process of preparing beads coated with a water soluble drug for incorporation into a pharmaceutical composition comprising: (a) preparing a supersaturated drug solution containing a desired amount of drug, which is completely saturated at a first temperature but which is supersaturated at a second temperature which is below the first temperature; and (b) coating inert beads with the drug solution, said drug solution being maintained at or below the first temperature but above the second temperature, and said beads maintained at a second temperature, wherein the second temperature is less than the first temperature and wherein the solution containing the drug is supersaturated at the second temperature, as well as to the pharmaceutical compositions containing same.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: December 9, 2014
    Assignee: Nostrum Pharmaceuticals, Inc.
    Inventor: Nirmal Mulye
  • Patent number: 8906392
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: December 9, 2014
    Assignee: University of Kansas
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Patent number: 8901113
    Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: December 2, 2014
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Ronald L. Leech, Rachelle L. Hall Yung, Albert W. Brzeczko
  • Patent number: 8895623
    Abstract: The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any non-central nervous system mediated systemic effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: November 25, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Petra Bloms-Funke, Derek John Saunders, Eric Lang
  • Publication number: 20140341988
    Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: APR APPLIED PHARMA RESEARCH SA
    Inventors: Alberto REINER, Giorgio REINER
  • Publication number: 20140343067
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 20, 2014
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
  • Publication number: 20140343159
    Abstract: Aspects of the present disclosure are directed to formulations that permit the solubilization and long term, stable storage of adrenergic agonist vasoconstrictors in organic solvents. Provided herein are formulations comprising about 250 mM to about 3000 mM of an acid salt of an adrenergic agonist vasoconstrictor dissolved in a pharmaceutically acceptable topical delivery vehicle comprising a water miscible, organic solvent having a water content of less than 40% by weight. Also provide are methods for using and kits containing such formulations.
    Type: Application
    Filed: March 9, 2012
    Publication date: November 20, 2014
    Applicant: ProCertus Biopharm, Inc.
    Inventor: William E. Fahl
  • Patent number: 8889627
    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: November 18, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Hussein Hallak, Nora Tarcic, Joel Flaxman Kaye
  • Publication number: 20140335206
    Abstract: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional management alternatives (such as suturing and/or administration of injected or systemic analgesia) are impractical, unaffordable or otherwise unavailable.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventors: Meridith Sheil, Allan Giffard, Charles R. Olsson
  • Patent number: 8877793
    Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: November 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Stuart D. Shanler, Andrew Ondo
  • Publication number: 20140323423
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: Chrono Therapeutics, Inc.
    Inventors: Guy DiPierro, Steven A. Giannos
  • Publication number: 20140322341
    Abstract: Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.
    Type: Application
    Filed: August 3, 2012
    Publication date: October 30, 2014
    Inventor: Diane RUBIN
  • Publication number: 20140323501
    Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.
    Type: Application
    Filed: July 5, 2012
    Publication date: October 30, 2014
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
  • Publication number: 20140316333
    Abstract: A dissolving solid solution perforator (SSP) patch for oral cavity administration may include at least one perforator. The at least one perforator may contain a first drug and be configured to pierce an outside layer of an oral cavity for promptly delivering the first drug. The at least one perforator may penetrate an epithelium layer of the oral cavity and to deliver the antimigraine drug into blood vessels in a submucosa layer.
    Type: Application
    Filed: October 29, 2012
    Publication date: October 23, 2014
    Inventor: Sung-Yun KWON
  • Publication number: 20140309291
    Abstract: Compositions and methods for increasing resilience to the effects of stress are provided.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 16, 2014
    Inventors: Seema Bhatnagar, Willem Heydendael, Abhishek Sengupta
  • Patent number: 8859623
    Abstract: The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: October 14, 2014
    Assignee: Paragon Bioteck, Inc.
    Inventors: Patrick H. Witham, Sailaja Machiraju, Lauren Mackensie-Clark Bluett
  • Patent number: 8859622
    Abstract: Drug substances comprising a pharmaceutically acceptable organic acid addition salt of amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: October 14, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: David William Bristol, Clifford Riley King, Joseph Pike Mitchener, Jr., Vicki Haynes Audia
  • Publication number: 20140294804
    Abstract: The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 2, 2014
    Applicant: SAINT LOUIS UNIVERSITY
    Inventor: Daniela SALVEMINI
  • Publication number: 20140296183
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Masatoshi KIUCHI, Kaoru MARUKAWA, Nobutaka KOBAYASHI
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Publication number: 20140275151
    Abstract: A liquid composition is provided. The composition includes at least one active pharmaceutical ingredient dissolved in a liquid carrier system. The liquid carrier includes polyethylene glycol and a co-solvent selected from the group consisting of: propylene glycol, glycerin, and a sugar alcohol. The composition is essentially dye tree, present as a single-phase at room temperature, and optionally contains water.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Inventors: Mahesh Sudhakar BHARATI, Houphouet Hyacinthe YARABE
  • Publication number: 20140271541
    Abstract: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: NOVARTIS AG
    Inventors: Carolyn Ann Foster, Peter C. Hiestand, Paul William Glue
  • Publication number: 20140271892
    Abstract: Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: McNeil-PPC, Inc.
    Inventor: McNeil-PPC, Inc.
  • Publication number: 20140271893
    Abstract: Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Vincent Chen, Robert Shen
  • Publication number: 20140271835
    Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventor: Simone Wengner
  • Publication number: 20140256688
    Abstract: A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water; and a pharmaceutical agent selected from the group consisting of pramoxine, phenylephrine, hydrocortisone, salicylic acid, nitroglycerine, sildenafil, or their salts and combinations thereof, wherein the composition is sufficiently designed to dry within 60 seconds after application to the anorectal mucosa to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Inventors: Evgenia Lozinsky, Eran Eilat
  • Publication number: 20140256822
    Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Inventor: John McCarty
  • Publication number: 20140255346
    Abstract: Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), MOG peptides (MOGps), proteolipid protein (PLP), and PLP peptides (PLPps). Stimulating PBMCs from patients with MS by CNS antigens cause B-lymphocytes to produce antibodies specific for CNS antigen, and causes T-lymphocytes to produce T-lymphocyte-specific cytokines, including interferon gamma (IFN-y), interleukin-2 (IL-2), or interleukin-17 (IL-17). In contrast, stimulating PBMCs from subjects without MS do not produce such responses.
    Type: Application
    Filed: May 3, 2012
    Publication date: September 11, 2014
    Applicant: Cellular Technology, Ltd.
    Inventors: Stefanie Kuerten, Paul Lehmann
  • Publication number: 20140248209
    Abstract: An anti-tumoral compound for the localized treatment of neoplastic pathologies of malignant kind that cannot be surgically removed or with a high risk of local recurrence, includes: a bicomponent injectable biologic glue; an antineoplastic substance; and an epinephrine-based solution. The compound may be used as an independent therapeutic treatment, as it allows to treat tumoral masses that are not surgically removable, or as a therapeutic treatment complementary to surgical removal or to known ablative techniques (laser, radiofrequency, microwaves, etc.) for a maximization of the efficiency of therapies reducing the risk of neoplastic relapses in the original surgical site. A process for the production of the antitumor compound is also described.
    Type: Application
    Filed: October 21, 2011
    Publication date: September 4, 2014
    Applicant: Seventeen SRL
    Inventor: Giulia Di Capua
  • Publication number: 20140248236
    Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
    Type: Application
    Filed: November 7, 2012
    Publication date: September 4, 2014
    Inventors: Michael G. Natchus, Richard Arrendale
  • Publication number: 20140249180
    Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 4, 2014
    Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHA
    Inventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
  • Publication number: 20140243364
    Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
    Type: Application
    Filed: February 27, 2014
    Publication date: August 28, 2014
    Applicant: Pfizer Inc
    Inventors: Gary Robert Agisim, Robert Alan Friedline, Shivangi Vijaykumar Patel, César Iván Sertzen, Vanessa Rose Shepperson
  • Publication number: 20140242177
    Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Applicant: NOVA SOUTHEASTERN UNIVERSITY
    Inventors: Mutasem Rawas-Qalaji, Keith Simons, Estelle Simons, Ousama Rachid
  • Publication number: 20140242169
    Abstract: The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a slow release Tapentadol Hydrochloride and a therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue.
    Type: Application
    Filed: May 13, 2014
    Publication date: August 28, 2014
    Applicant: GRUENENTHAL GMBH
    Inventor: RAMESH SESHA
  • Publication number: 20140242151
    Abstract: The present invention provides an adhesive skin patch that permits excellent and prolonged percutaneous absorption of tulobuterol and that can be stably applied to the skin for a long period of time with less skin irritation. The adhesive skin patch comprises a base material and a medicated layer provided on one surface of the base material. The medicated layer contains 1 to 30% by weight of a resolvent, 40 to 98% by weight of a pressure-sensitive adhesive, and tulobuterol. The resolvent contains an aliphatic alcohol having a branched-chain structure or a double bond in its C8 to C30 carbon chain. The pressure-sensitive adhesive is a copolymer obtained by copolymerizing monomers containing 70% by weight or more of an alkyl(meth)acrylate whose alkyl group has 6 to 20 carbon atoms.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: Sekisui Chemical Co., Ltd.
    Inventors: Hiroko UDAGAWA, Toshikazu KOMODA, Masaru HAMABE
  • Patent number: 8815292
    Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: August 26, 2014
    Assignee: Revalesio Corporation
    Inventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
  • Publication number: 20140235610
    Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.
    Type: Application
    Filed: December 5, 2013
    Publication date: August 21, 2014
    Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben DEOGRACIAS, Rainer R. KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART
  • Publication number: 20140230812
    Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).
    Type: Application
    Filed: October 12, 2012
    Publication date: August 21, 2014
    Applicant: Mexichem Amanco Holdings S.A. de C.V.
    Inventors: Stuart Corr, Timothy James Noakes
  • Publication number: 20140228355
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 14, 2014
    Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
    Inventors: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, University of Medicine and Dentistry New Jersey Medical School
  • Publication number: 20140228445
    Abstract: The present invention relates to alkyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: February 11, 2014
    Publication date: August 14, 2014
    Applicant: Allergan, Inc.
    Inventors: Wenkui K. Fang, Ken Chow, Evelyn G. Corpuz, Wha Bin Im
  • Publication number: 20140228446
    Abstract: The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Inventors: Peter C. Hiestand, Christian Schnell
  • Publication number: 20140227358
    Abstract: The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Michael AMBUHL, Jutta BEYER, Begona CARRENO-GOMEZ, Colleen RUEGGER, Stephen VALAZZA
  • Publication number: 20140228402
    Abstract: The invention relates to a combination which comprises fingolimod and at least antidepressant compound.
    Type: Application
    Filed: September 7, 2012
    Publication date: August 14, 2014
    Applicant: Novartis AG
    Inventors: Matthias Meergans, Ferenc Tracik, Katrin Schuh
  • Publication number: 20140228391
    Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.
    Type: Application
    Filed: February 13, 2014
    Publication date: August 14, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
  • Publication number: 20140228443
    Abstract: Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Feng Hong, Ryo Kubota, Jennifer Gage
  • Publication number: 20140228380
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Application
    Filed: August 2, 2013
    Publication date: August 14, 2014
    Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
    Inventors: Sandhya Kortagere, Eldo V. Kuzhikandahil